OMERS ADMINISTRATION Corp Lowers Position in Zoetis Inc. $ZTS

OMERS ADMINISTRATION Corp decreased its position in Zoetis Inc. (NYSE:ZTS) by 14.2% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 16,451 shares of the company’s stock after selling 2,727 shares during the period. OMERS ADMINISTRATION Corp’s holdings in Zoetis were worth $2,709,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. Vanguard Group Inc. boosted its holdings in shares of Zoetis by 0.5% in the first quarter. Vanguard Group Inc. now owns 41,556,164 shares of the company’s stock valued at $6,842,222,000 after acquiring an additional 189,287 shares in the last quarter. Polen Capital Management LLC boosted its holdings in shares of Zoetis by 17.6% in the first quarter. Polen Capital Management LLC now owns 8,796,847 shares of the company’s stock valued at $1,448,401,000 after acquiring an additional 1,313,653 shares in the last quarter. Northern Trust Corp boosted its holdings in shares of Zoetis by 1.2% in the first quarter. Northern Trust Corp now owns 6,504,902 shares of the company’s stock valued at $1,071,032,000 after acquiring an additional 78,508 shares in the last quarter. Goldman Sachs Group Inc. boosted its holdings in shares of Zoetis by 2.2% in the first quarter. Goldman Sachs Group Inc. now owns 5,146,024 shares of the company’s stock valued at $847,293,000 after acquiring an additional 109,791 shares in the last quarter. Finally, Brown Advisory Inc. boosted its holdings in shares of Zoetis by 7.6% in the first quarter. Brown Advisory Inc. now owns 4,408,542 shares of the company’s stock valued at $725,866,000 after acquiring an additional 312,746 shares in the last quarter. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Zoetis Stock Performance

Shares of ZTS opened at $156.45 on Friday. The company has a current ratio of 1.76, a quick ratio of 1.04 and a debt-to-equity ratio of 1.05. The stock has a market cap of $69.34 billion, a P/E ratio of 26.93, a PEG ratio of 2.48 and a beta of 0.88. The company has a 50-day moving average of $153.51 and a two-hundred day moving average of $158.02. Zoetis Inc. has a 12-month low of $139.70 and a 12-month high of $200.33.

Zoetis (NYSE:ZTS) last announced its earnings results on Tuesday, August 5th. The company reported $1.76 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.62 by $0.14. The company had revenue of $2.46 billion during the quarter, compared to analysts’ expectations of $2.41 billion. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. The firm’s quarterly revenue was up 4.2% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.56 earnings per share. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. As a group, research analysts predict that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on ZTS. Stifel Nicolaus downgraded shares of Zoetis from a “buy” rating to a “hold” rating and lowered their target price for the company from $165.00 to $160.00 in a report on Wednesday, June 18th. Leerink Partnrs downgraded shares of Zoetis from a “strong-buy” rating to a “hold” rating in a report on Thursday, July 17th. UBS Group decreased their price objective on shares of Zoetis from $189.00 to $170.00 and set a “neutral” rating on the stock in a report on Wednesday, May 7th. Piper Sandler boosted their price objective on shares of Zoetis from $210.00 to $215.00 and gave the stock an “overweight” rating in a report on Monday, August 11th. Finally, Leerink Partners downgraded shares of Zoetis from an “outperform” rating to a “market perform” rating and decreased their price objective for the stock from $180.00 to $155.00 in a report on Thursday, July 17th. Four investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $202.43.

Insider Transactions at Zoetis

In other Zoetis news, EVP Roxanne Lagano sold 652 shares of Zoetis stock in a transaction dated Tuesday, June 3rd. The shares were sold at an average price of $170.00, for a total transaction of $110,840.00. Following the completion of the transaction, the executive vice president owned 15,129 shares in the company, valued at approximately $2,571,930. The trade was a 4.13% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 0.18% of the company’s stock.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.